Physician profile
Robert C Thomson
NPI 1144267329
$9,364.39
in general payments reported to CMS, 2019-2025
51 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $741 · 2021: $967 · 2022: $1,376 · 2023: $1,611 · 2024: $1,782 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,723 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,723.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,452.26 | 2021-2025 | Vraylar, Ubrelvy, Creon |
| Novo Nordisk INC | $863.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $784.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $740.65 | 2019-2025 | |
| Lilly USA, LLC | $614.67 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Glaxosmithkline, LLC. | $600.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $474.67 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.29 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $338.68 | 2019-2025 | |
| Astellas Pharma US INC | $292.34 | 2019-2024 | Myrbetriq, Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.43 | 2019-2024 | Xifaxan |
| Baxter Healthcare | $207.90 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $206.00 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.39 | 2023-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $157.96 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Thomson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.